PregLem
PregLem, acquired by the Richter Group in 2010 for 445 million Swiss Francs, is a Swiss-based specialty Biopharma company dedicated to the development and commercialization of innovative drugs for women’s reproductive medicine. PregLem’s activities focus on developing therapies for gynecologic conditions with significant unmet needs and that have a severe impact on the patient’s quality of life: uterine fibroids, endometriosis, infertility through ovarian reserve modulation, and post-surgical adhesions.
Sector
Biopharmaceuticals
Strategies
Status
Exit
Website
www.preglem.com
Related News
The Sofinnova Capital Strategy is our flagship fund, investing as founding or lead investor in early-stage biopharma and medtech start-ups developing groundbreaking therapeutic technologies.
The Sofinnova MD Start Strategy is our in-house medtech accelerator focused on creating and launching early-stage medtech companies through hands-on company building.
The Sofinnova Crossover Strategy invests in growth-stage biotech and medtech companies that have clinically validated their technologies and are preparing for commercialization.
Our Industrial Biotech Strategy invests in early-stage sustainable companies across the agriculture, chemicals, food and materials sectors.
The Sofinnova Telethon Strategy makes early-stage investments in leading Italian science for the benefit of patients around the world.
Our Digital Medicine Strategy backs early-stage techbio and healthtech start-ups at the intersection of biology, data, and computation.
The Sofinnova Biovelocita Strategy is our biotech accelerator, partnering with leading research organizations to create and build European biotech start-ups.